Lilly to transform chronic disease management with Sigilon Therapeutics acquisition
Pharmaceutical giant Eli Lilly and Company (Lilly) has announced its definitive agreement to acquire Nasdaq-listed biopharma innovator Sigilon Therapeutics, in a move set to significantly impact the biopharmaceutical industry and the treatment of chronic diseases. The deal, valued at approximately $309.6 million excluding shares held by Lilly, not only promises to reshape the landscape of […]